Brandon Capital Partners related stories
All articles and analysis
Allay Therapeutics scores $60m Series CAllay Therapeutics, a clinical-stage biotechnology company, has raised $60 million in Series C financing.
Myricx nabs seed fundingUK-based Myricx Pharma, a drug discovery company, has secured 4.5 million pounds in seed financing.
- Glyscend Therapeutics rakes in $20.5m Series A
Baltimore-based Glyscend Therapeutics, a developer of novel treatments for type 2 diabetes and related metabolic conditions, has closed $20.5 million in Series A financing.
EBR Systems nets $30 mlnSilicon Valley-based EBR Systems, a developer of a wireless cardiac pacing system for heart failure, has secured $30 million in funding. Brandon Capital Partners and M.H. Carnegie & Co. led the round. In conjunction with the funding, EBR Systems has appointed John McCutcheon as president and CEO.
- EBR Systems amasses $50 mln
Sunnyvale, California-based EBR Systems Inc, a wireless cardiac pacing system provider for heart failure, has raised $50 million in funding. M.H. Carnegie & Co. and Brandon Capital Partners led the round with participation from other backers that included Split Rock Partners, Ascension Ventures and Emergent Medical Partners.
- Aussie life science venture firm Brandon Capital opens U.S. office
Australian life science venture firm Brandon Capital Partners has opened a new office in Palo Alto, California. J. Leighton Read has joined the firm as a venture partner and will head the Palo Alto office.
- Elastagen snags A$13 mln Series B
Elastagen Pty Ltd, an Australian developer of products based on recombinant human tropoelastin platform technology, has raised A$13 milion in Series B funding. The investors included Korea Investment Partners, AMOREPACIFIC Ventures, Wellcome Trust, Brandon Capital Partners, GBS Ventures and ATP Innovations. In addition to the funding, Sangwoo Lee of KIP has been added to Elastagen's board of directors.
- Novartis to buy Spinifex for $200 mln
Novartis International AG has agreed to buy Spinifex Pharmaceuticals Inc. for an upfront cash consideration of $200 million plus undisclosed clinical development and regulatory milestone payments. based in Stamford, Connecticut and Melbourne, Australia, Spinifex develops drugs for the treatment of chronic pain. Deutsche Bank advised Spinifex. Spinifex's investors include Novo A/S, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest (University of Queensland, Australia).
- Auspherix raises $9.2 mln
Auspherix Limited (UK) has raised £6 million (US$9.2 million) in a Series A venture financing. Imperial Innovations plc led the round alongside Australian founding investor the Medical Research Commercialisation Fund. Stevenage, United Kingdom-based Auspherix is an an early stage anti-infectives company.
- Brandon Capital MRCF fund raises $154.4 mln
Brandon Capital said Monday that its Medical Research Commercialisation Fund closed at AU$200 million (US$154.4 million). Existing MRCF Investors AustralianSuper and Statewide Super participated. Hesta, an existing investor in Brandon funds, took part as well HOSTPLUS. Around AU$50M of the new fund will be reserved for 20 to 30 very early seed stage investments in biotech or medical device technologies.